Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; and Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer. The company's pipeline products focuses on the research and development of enhancing Cologuard's performance characteristics, and blood or other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; Biocartis N.V.; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Date	Fund	Action	%
2023/09/07	ARKK	Sell	0.0088
2023/09/07	ARKG	Sell	0.0071
2023/09/06	ARKK	Sell	0.0436
2023/09/06	ARKG	Sell	0.0325
2023/08/28	ARKK	Sell	0.0325
2023/08/25	ARKK	Sell	0.0216
2023/08/23	ARKK	Sell	0.0303
2023/08/22	ARKK	Sell	0.028
2023/08/17	ARKK	Sell	0.0863
2023/08/17	ARKG	Sell	0.0461
2023/08/16	ARKK	Sell	0.0875
2023/08/11	ARKK	Sell	0.035
2023/08/10	ARKK	Sell	0.1678
2023/07/26	ARKG	Sell	0.0411
2023/07/25	ARKG	Sell	0.2933
2023/07/24	ARKG	Sell	0.1586
2023/06/21	ARKK	Sell	0.0033
2023/06/21	ARKG	Sell	0.048
2023/06/20	ARKK	Sell	0.1043
2023/06/20	ARKG	Sell	0.0637
2023/06/16	ARKK	Sell	0.0317
2023/06/16	ARKG	Sell	0.0181
2023/06/15	ARKK	Sell	0.024
2023/06/07	ARKK	Sell	0.2287
2023/06/06	ARKK	Sell	0.0676
2023/06/05	ARKK	Sell	0.0333
2023/06/05	ARKG	Sell	0.0283
2023/06/02	ARKK	Sell	0.0255
2023/06/02	ARKG	Sell	0.0245
2023/05/25	ARKK	Sell	0.1702